Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping Chen-Hua Liu,a,b,c,d Cheng-Chao Liang,e Chun-Jen Liu,a,b,c Chih-Lin Lin,f Tung-Hung Su,a,b,c Hung-Chih Yang,a,b,c,g Pei-Jer Chen,a,b,c

Genotyping and subtyping of 225 samples with hepatitis C virus (HCV) genotype 1, 2, 3, or 6 infection were done with Versant LiPA 2.0 and Abbott RealTime HCVGenotype (GT) II by using direct sequencing of the NS5B and 5 = untranslated regions as the reference standards. The concordance rates were>99.2 % for genotypes and 96.1 % for subtypes 1a and 1b. Both the Abbott Real-Time and Versant LiPA assays can accurately determine hepatitis C virus genotypes. (This study has been registered at Clinical-Trials.gov under registration no. NCT00979979.) In this retrospective hepatitis C virus (HCV) study (which hasbeen registered at ClinicalTrials.gov under registration no. NCT00979979.), the Versant LiPA HCV 2.0 (V-LiPA-2) (1–5), the Abbott RealTime HCV GT II assay (Abbott-RT-HCV) (6, 7), and sequencing of the 5 = untranslated region (UTR) and NS5B genes were used to genotype 225 samples from patients with HCV monoinfection and HCV-HBV or HCV-HIV dual infection. Reverse transcription, PCR amplification, and sequencing were performed with the ABI BigDye Terminator kit (see Table S1 in the supplemental material), and the samples were analyzed with the ABI 7900HT sequence detection system (Applied Biosystems